The goal of this Predoctoral Immunology Training Program is to provide academia, industry, and governmental research laboratories with highly creative and productive immunologists who are broadly trained in immunology, well trained in their research specialty and equipped to address today's important immunological questions. This will be achieved by having the predoctoral students follow a defined set of program-specific courses as part of the Immunology Track set in the established interdepartmental graduate training milieu of the University of Rochester School of Medicine and Dentistry (URSMD). The environment will be fostered by a diverse and interactive faculty composed of both basic and translational researchers, who are dedicated to excellence in teaching and collaborative research and committed to immunology training; active immunological research programs of trainees and their mentors; structured lecture and seminar courses at the basic and advanced levels; an active seminar series, and by a catalytic number of trainees. This will occur by integrating a core of faculty within the Department of Microbiology & Immunology and the Centers for Vaccine Biology and Human Immunology with faculty from other departments and disciplines, particularly those with strong clinical/translational research interests. Research training opportunities in a wide variety of immunological problems relevant to cancer, infectious diseases and autoimmunity will be offered by an experienced, training faculty with strong records of extramural funding and an established history of collaboration. The program will be governed by a Steering Committee composed of the Program Director, the Associate Director and three senior faculty members. The learning environment will be further enriched with workshops to support trainee career development, enhanced training in the responsible conduct of research, and opportunities for training in mentoring. Students will also be trained in scientifc writing, with an emphasis on manuscripts and grant applications. Since the previous competitive renewal of this application, we have broadened the research opportunities available, integrated this training program with the University of Rochester Clinical & Translational Science Institute (CTSI), added new immunology-specific courses, and developed an innovative peer/near-peer evaluation process to enhance trainee career development. An External Advisory Board has been added to assist with oversight of the program. We will continue to strengthen our already successful strategies to recruit and nurture minority and women students and to provide all of the trainees with the essential skills to become independent scientists with an appreciation for the ethical conduct of research. These trained scientists will provide the next generation of researchers and teachers to further the advances in basic science and translational studies needed to improve healthcare in this country. Training support is requested for 6 predoctoral students in each of five years.

Public Health Relevance

The goal of this predoctoral program is to train highly versatile, productive, independent research immunologists. To do this, trainees will be equipped with a broad range of skills and knowledge of cellular and molecular immunology as well as training in translational research, career development, cutting edge scientific techniques, mentoring and other issues important to their scientific future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
4T32AI007285-29
Application #
9058479
Study Section
Allergy, Immunology, and Transplantation Research Committee (AITC)
Program Officer
Gondre-Lewis, Timothy A
Project Start
1986-09-30
Project End
2018-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
29
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Rochester
Department
Microbiology/Immun/Virology
Type
School of Medicine & Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Boule, Lisbeth A; Burke, Catherine G; Jin, Guang-Bi et al. (2018) Aryl hydrocarbon receptor signaling modulates antiviral immune responses: ligand metabolism rather than chemical source is the stronger predictor of outcome. Sci Rep 8:1826
Cameron, Scott J; Mix, Doran S; Ture, Sara K et al. (2018) Hypoxia and Ischemia Promote a Maladaptive Platelet Phenotype. Arterioscler Thromb Vasc Biol 38:1594-1606
Richards, Katherine A; DiPiazza, Anthony T; Rattan, Ajitanuj et al. (2018) Diverse Epitope Specificity, Immunodominance Hierarchy, and Functional Avidity of Effector CD4 T Cells Established During Priming Is Maintained in Lung After Influenza A Virus Infection. Front Immunol 9:655
DiPiazza, Anthony; Laniewski, Nathan; Rattan, Ajitanuj et al. (2018) CD4 T Cell Epitope Specificity and Cytokine Potential Are Preserved as Cells Transition from the Lung Vasculature to Lung Tissue following Influenza Virus Infection. J Virol 92:
Simpson, Sydney; Fiches, Guillaume; Jean, Maxime J et al. (2018) Inhibition of Tip60 Reduces Lytic and Latent Gene Expression of Kaposi's Sarcoma-Associated Herpes Virus (KSHV) and Proliferation of KSHV-Infected Tumor Cells. Front Microbiol 9:788
DiPiazza, Anthony; Richards, Katherine; Poulton, Nicholas et al. (2017) Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity. Clin Vaccine Immunol 24:
Murphy, Patrick S; Wang, Jing; Bhagwat, Samir P et al. (2017) CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages. Cell Death Differ 24:559-570
DiPiazza, Anthony; Nogales, Aitor; Poulton, Nicholas et al. (2017) Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo. Sci Rep 7:10857
Hayashi, Tsuyoshi; Jean, Maxime; Huang, Huachao et al. (2017) Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res 146:76-85
Jean, Maxime J; Hayashi, Tsuyoshi; Huang, Huachao et al. (2017) Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. Front Microbiol 8:2007

Showing the most recent 10 out of 151 publications